Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pallone on supplements

This article was originally published in The Tan Sheet

Executive Summary

Recent statements by FDA Commissioner Mark McClellan, MD/PhD, implying a need to "crack down" on dietary supplements "create unnecessary concern among consumers and are grossly unfair to the industry as a whole," Rep. Frank Pallone (D-N.J.) states in Dec. 20 letter to agency head. Referring to McClellan's Dec. 18 announcement of FDA, FTC intentions to target misleading supplement claims, the Congressman notes such statements "give the impression that the entire industry is at fault, rather than those few manufacturers that are not in compliance" (1"The Tan Sheet" Dec. 23, 2002, p. 11). Pallone criticizes FDA's "ineffective and inefficient" attempts to implement DSHEA, requests meeting "to discuss federal legislation regarding" supplements and Congress' expectations for agency...

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS094973

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel